Identification and Validation of Nicotinamide Metabolism-Related Gene Signatures As a Novel Prognostic Model for Hepatocellular Carcinoma

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2024 Jun 3

PMID 38827823

Authors

Sijia Yang

Ang Li

Lihong Lv

Jinxin Duan

Zhihua Zheng

Wenfeng Zhuo

Jun Min

Jinxing Wei

Affiliations

Soon will be listed here.

Abstract

Background: Nicotinamide (NAM+) regulates redox and metabolic activities in the mitochondria. The intention of the research was to identify key genes that relate to nicotinamide in hepatocellular carcinoma (HCC).

Methods: Relevant clinical information were collected as well as RNA-seq data using the Cancer Genome Atlas (TCGA) database. Differential analysis was used to discover the genes that were differently expressed. On the key genes associated with NAM, functional enrichment analysis was carried out. Next, receiver operating characteristic (ROC) and prognosis Kaplan-Meier (K-M) curve analyses were used to evaluate the importance of important gene expression, respectively. The immune cell signatures were estimated using the CIBERSORT algorithm. Finally, the anticancer impact of NAM on HCC was experimentally confirmed, and important genes NADSYN1 and NT5C were validated at the protein level in clinical specimens.

Results: Six prognostic key genes (NAXE, NADSYN1, NT5C, NT5C3A, PNP and NT5E) were identified. There is an association between the level of key gene expression and the clinical prognosis. Four key genes (NAXE, NADSYN1, NT5C and NT5C3A) have statistical significance of survival prognosis. Finally, the expression of NAM-related genes and the inhibitory effect of NAM on HCC were verified by experiments.

Conclusion: The study first found some Nicotinamide metabolism-related differentially expressed genes (NMRDEGs) that are related to HCC can contribute to predicting survival and monitoring the treatment.

Citing Articles

A nicotinamide metabolism-related gene signature for predicting immunotherapy response and prognosis in lung adenocarcinoma patients.

Wang M, Li W, Zhou F, Wang Z, Jia X, Han X PeerJ. 2025; 13:e18991.

PMID: 40034678 PMC: 11874940. DOI: 10.7717/peerj.18991.

References

Chen A, Martin A, Choy B, Fernandez-Penas P, Dalziell R, McKenzie C . A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med. 2015; 373(17):1618-26. DOI: 10.1056/NEJMoa1506197. View

Hsu P, Sabatini D . Cancer cell metabolism: Warburg and beyond. Cell. 2008; 134(5):703-7. DOI: 10.1016/j.cell.2008.08.021. View

Mayakonda A, Lin D, Assenov Y, Plass C, Koeffler H . Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018; 28(11):1747-1756. PMC: 6211645. DOI: 10.1101/gr.239244.118. View

Ivanovska I, Zhang C, Liu A, Wong K, Lee N, Lewis P . Gene signatures derived from a c-MET-driven liver cancer mouse model predict survival of patients with hepatocellular carcinoma. PLoS One. 2011; 6(9):e24582. PMC: 3174972. DOI: 10.1371/journal.pone.0024582. View

Barrett T, Wilhite S, Ledoux P, Evangelista C, Kim I, Tomashevsky M . NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2012; 41(Database issue):D991-5. PMC: 3531084. DOI: 10.1093/nar/gks1193. View

Chen Y, Wang T, Hsu H, Yuan R, Jeng Y . Overexpression of CTHRC1 in hepatocellular carcinoma promotes tumor invasion and predicts poor prognosis. PLoS One. 2013; 8(7):e70324. PMC: 3726622. DOI: 10.1371/journal.pone.0070324. View

DeBerardinis R, Chandel N . Fundamentals of cancer metabolism. Sci Adv. 2016; 2(5):e1600200. PMC: 4928883. DOI: 10.1126/sciadv.1600200. View

Trinh J, Imhoff S, Dulovic-Mahlow M, Kandaswamy K, Tadic V, Schafer J . Novel NAXE variants as a cause for neurometabolic disorder: implications for treatment. J Neurol. 2019; 267(3):770-782. DOI: 10.1007/s00415-019-09640-2. View

Fishilevich S, Nudel R, Rappaport N, Hadar R, Plaschkes I, Iny Stein T . GeneHancer: genome-wide integration of enhancers and target genes in GeneCards. Database (Oxford). 2017; 2017. PMC: 5467550. DOI: 10.1093/database/bax028. View

10.

Parrinello S, Coppe J, Krtolica A, Campisi J . Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J Cell Sci. 2005; 118(Pt 3):485-96. PMC: 4939801. DOI: 10.1242/jcs.01635. View

11.

Wang H, Huo X, Yang X, He J, Cheng L, Wang N . STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. Mol Cancer. 2017; 16(1):136. PMC: 5558651. DOI: 10.1186/s12943-017-0680-1. View

12.

Tlemsani C, Pongor L, Elloumi F, Girard L, Huffman K, Roper N . SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures. Cell Rep. 2020; 33(3):108296. PMC: 7643325. DOI: 10.1016/j.celrep.2020.108296. View

13.

Donne R, Lujambio A . The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma. Hepatology. 2022; 77(5):1773-1796. PMC: 9941399. DOI: 10.1002/hep.32740. View

14.

Mermel C, Schumacher S, Hill B, Meyerson M, Beroukhim R, Getz G . GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41. PMC: 3218867. DOI: 10.1186/gb-2011-12-4-r41. View

15.

Van Bergen N, Walvekar A, Patraskaki M, Sikora T, Linster C, Christodoulou J . Clinical and biochemical distinctions for a metabolite repair disorder caused by NAXD or NAXE deficiency. J Inherit Metab Dis. 2022; 45(6):1028-1038. PMC: 9804276. DOI: 10.1002/jimd.12541. View

16.

Harris M, Clark J, Ireland A, Lomax J, Ashburner M, Foulger R . The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res. 2003; 32(Database issue):D258-61. PMC: 308770. DOI: 10.1093/nar/gkh036. View

17.

Zapata-Perez R, Wanders R, van Karnebeek C, Houtkooper R . NAD homeostasis in human health and disease. EMBO Mol Med. 2021; 13(7):e13943. PMC: 8261484. DOI: 10.15252/emmm.202113943. View

18.

Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View

19.

Park S, Lee K, Lee M, Bae S, Jang J . Nicotinamide inhibits the early stage of carcinogen-induced hepatocarcinogenesis in mice and suppresses human hepatocellular carcinoma cell growth. J Cell Physiol. 2011; 227(3):899-908. DOI: 10.1002/jcp.22799. View

20.

Nault J, Ningarhari M, Rebouissou S, Zucman-Rossi J . The role of telomeres and telomerase in cirrhosis and liver cancer. Nat Rev Gastroenterol Hepatol. 2019; 16(9):544-558. DOI: 10.1038/s41575-019-0165-3. View